The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Open accessAbstract
Background Compulsive sexual behaviour disorder is a new disorder in the International Classification of Diseases (ICD-11), and is associated with negative consequences in different areas of life. Evidence for pharmacological treatment of compulsive sexual behaviour disorder is weak and treatment options are limited. This proposed study will be the largest and the first randomised controlled trial comparing the efficacy and tolerability of two active drugs in compulsive sexual behaviour disorder. Methods and analysis Eighty adult participants with compulsive sexual behaviour disorder according to ICD-11 will be randomised to receive either naltrexone 25–50 mg or fluoxetine 20–40 mg for 8 weeks, followed by 6 weeks without treatment. The study will be conducted in a subspecialised outpatient sexual medicine unit at Karolinska University Hospital, Stockholm, Sweden. The study is financed by grants and entirely independent of the manufacturers. Exclusion criteria include severe psychiatric or psychical illness, changes to concurrent medication and non-compatible factors contraindicating the use of either drug. The primary outcome measure is the Hypersexual Disorder: Current Assessment Scale (HD: CAS), and tolerability will be assessed by the Udvalg for Kliniske Undersogelser side effect rating scale (UKU), drug accountability, adherence to treatment and drop-out rate. Participants will complete questionnaires at regular intervals, with the main endpoint for efficacy after 8 weeks (end of treatment) and after 14 weeks (follow-up). Blood chemistry will be repeatedly collected as a safety precaution and for research purposes. The results will be analysed using an appropriate analysis of variance model or a mixed model, depending on the distribution of HD: CAS and the extent of missing data. Ethics and dissemination The Swedish Ethical Review Authority and the Swedish Medical Products Agency have approved the study on 27 May 2020 and 4 June 2020, respectively (ref. no. 2020-02069 and ref. no. 5.1-2020-48282). Findings will be published in peer-reviewed journals and presented at relevant conferences. Trial registration number 2019-004255-36
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Immunopathogenic mechanisms of systemic autoimmune disease
Wahren-Herlenius, M., & Dörner, T. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60954-x · Cited by 593
Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T. H., Kalden, J. R., Manz, R. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1763 · Cited by 584
Self-citationProteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2258 · Cited by 410
Self-citationBortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318190af83 · Cited by 392
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
Hiepe, F., Dörner, T., Hauser, A. E., Hoyer, B. F., Mei, H., & Radbruch, A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.1 · Cited by 389
Self-citationIchikawa, H. T., Conley, T., Muchamuel, T., Jiang, J., Lee, S., Owen, T., Barnard, J., Nevarez, S., Goldman, B. I., Kirk, C. J., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33333 · Cited by 244
Cited by
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Novel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
Mechanisms of Autoantibody-Induced Pathology
Ludwig, R. J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S. M., Komorowski, L., Luo, J., Cabral-Marques, O., Hammers, C. M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00603 · Cited by 469
Metadata
- Authors
- Alexander, T., Sarfert, R., Klotsche, J., Kühl, A. A., Rubbert-Roth, A., Lorenz, H.-M., Rech, J., Hoyer, B. F., Cheng, Q., Waka, A., Taddeo, A., Wiesener, M., Schett, G., Burmester, G.-R., Radbruch, A., Hiepe, F., & Voll, R. E.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 74
- Issue
- 7
- Pages
- 1474-1478
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2146853551
- Cited by
- 368
- References
- 19
- FWCI
- 26.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. https://app.cochat.ai/papers/10.1136/annrheumdis-2014-206016
- The paper
- Alexander, T., Sarfert, R., Klotsche, J., Kühl, A. A., Rubbert-Roth, A., Lorenz, H.-M., Rech, J., Hoyer, B. F., Cheng, Q., Waka, A., Taddeo, A., Wiesener, M., Schett, G., Burmester, G.-R., Radbruch, A., Hiepe, F., & Voll, R. E. (2015). The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2014-206016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.